Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)

Benzer Materyaller

• The Canakinumab Antiinflammatory Thrombosis Outcome Study trial—the starting gun has fired
  Yazar:: Crossman, David, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
  Yazar:: Lorenzatti, Alberto, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial
  Yazar:: Thompson, Peter L., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Canakinumab (an interleukin 1β inhibitor) is a breakthrough in the possibilities of anti-inflammatory therapy for gout
  Yazar:: Maksim Sergeevich Eliseev, ve diğerleri
  Baskı/Yayın Bilgisi: (2013-11-01)
• Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report
  Yazar:: Niccoli, Laura, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)